UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Desensitization Protocols and Their Outcome

Clinical journal of the American Society of Nephrology, 2011-04, Vol.6 (4), p.922-936

2011

Volltextzugriff (PDF)

Barriers and facilitators to community acceptability of integrating point-of-care testing to screen for sickle cell disease in children in primary healthcare settings in rural Upper East Region of Northern Ghana

PloS one, 2024-05, Vol.19 (5), p.e0303520-e0303520

2024

Volltextzugriff (PDF)

Long-term Safety of Secukinumab Over Five Years in Patients with Moderate-to-severe Plaque Psoriasis, Psoriatic Arthritis and Ankylosing Spondylitis: Update on Integrated Pooled Clinical Trial and Post-marketing Surveillance Data

Acta dermato-venereologica, 2022-04, Vol.102, p.adv00698-adv00698

2022

Volltextzugriff (PDF)

Bridging the Access Gap for Comprehensive Sickle Cell Disease Management Across Sub-Saharan Africa: Learnings for Other Global Health Interventions?

Annals of global health, 2023-01, Vol.89 (1), p.76-76

2023

Volltextzugriff (PDF)

Evaluation of treatment patterns, healthcare resource utilization and cost of illness for sickle cell disease in Ghana: a private medical insurance claims database study

BMC health services research, 2023-09, Vol.23 (1), p.1-1018, Article 1018

2023

Volltextzugriff (PDF)

Clinical efficacy and safety of secukinumab in patients with psoriasis and comorbidities: pooled analysis of 4 phase 3 clinical trials

The Journal of dermatological treatment, 2022-04, Vol.33 (3), p.1482-1490

2022

Volltextzugriff (PDF)

PB2512: SAFETY OF CRIZANLIZUMAB IN PATIENTS WITH SICKLE CELL DISEASE: INTEGRATED POST‐MARKETING SURVEILLANCE ANALYSIS

HemaSphere, 2023-08, Vol.7 (S3), p.e4608172-n/a

2023

Volltextzugriff (PDF)

Clinical and economic analysis of short-course versus standard-course antithymocyte globulin (rabbit) induction therapy in deceased-donor renal transplant recipients

American journal of health-system pharmacy, 2011-12, Vol.68 (23), p.2276-2282

2011

Volltextzugriff (PDF)

Tacrolimus Pharmacokinetic and Pharmacogenomic Differences between Adults and Pediatric Solid Organ Transplant Recipients

Pharmaceutics, 2010-09, Vol.2 (3), p.291-299

2010

Volltextzugriff (PDF)

Reply to "Defining the benefits of desensitization therapy"

Transplantation, 2013-03, Vol.95 (6), p.e33-e34

2013

Volltextzugriff (PDF)

Barriers and Facilitators to Community Acceptability of Integrating Point-of-Care Testing to Screen for Sickle Cell Disease in Children in Primary Healthcare Settings in Rural Northern Ghana

Blood, 2022-11, Vol.140 (Supplement 1), p.5018-5018

2022

Volltextzugriff (PDF)

Association of Secukinumab Treatment With Tuberculosis Reactivation in Patients With Psoriasis, Psoriatic Arthritis, or Ankylosing Spondylitis

JAMA dermatology (Chicago, Ill.), 2021-01, Vol.157 (1), p.43

2021

Volltextzugriff (PDF)

Safety Profile of Crizanlizumab 5.0 Mg/Kg in Sickle Cell Disease: Pooled Data from Clinical Trials

Blood, 2023-11, Vol.142 (Supplement 1), p.1139-1139

2023

Volltextzugriff (PDF)

15353 Presence of psoriatic arthritis has no impact on the clinical efficacy and safety of secukinumab in patients with psoriasis: Pooled analysis of four phase 3 clinical trials

Journal of the American Academy of Dermatology, 2020-12, Vol.83 (6), p.AB148-AB148

2020

Volltextzugriff (PDF)

Pretransplant immunologic risk assessment of kidney transplant recipients with donor-specific anti-human leukocyte antigen antibodies

Transplantation, 2014-11, Vol.98 (10), p.1082-1088

2014

Volltextzugriff (PDF)

Hyponatremia in Cirrhosis and End-Stage Liver Disease: Treatment with the Vasopressin V2-Receptor Antagonist Tolvaptan

Digestive diseases and sciences, 2012-11, Vol.57 (11), p.2774-2785

2012

Volltextzugriff (PDF)

P191 Secukinumab demonstrates a consistent safety profile in patients with psoriasis, psoriatic arthritis and ankylosing spondylitis over long term: updated pooled safety analyses

Rheumatology (Oxford, England), 2021-04, Vol.60 (Supplement_1)

2021

Volltextzugriff (PDF)

Lack of effect in desensitization with intravenous immunoglobulin and rituximab in highly sensitized patients

Transplantation, 2012-08, Vol.94 (4), p.345-351

2012

Volltextzugriff (PDF)

Hyponatremia in Cirrhosis and End-Stage Liver Disease: Treatment with the Vasopressin V^sub 2^-Receptor Antagonist Tolvaptan

Digestive diseases and sciences, 2012-11, Vol.57 (11), p.2774

2012

Volltextzugriff (PDF)

Hyponatremia in Cirrhosis and End-Stage Liver Disease: Treatment with the Vasopressin V sub(2)-Receptor Antagonist Tolvaptan

Digestive diseases and sciences, 2012-11, Vol.57 (11), p.2774-2785

2012

Volltextzugriff (PDF)

Hyponatremia in Cirrhosis and End-Stage Liver Disease: Treatment with the Vasopressin V.sub.2-Receptor Antagonist Tolvaptan

Digestive diseases and sciences, 2012-11, Vol.57 (11), p.2774

2012

Volltextzugriff (PDF)

Clinical outcomes after conversion from brand-name tacrolimus (prograf) to a generic formulation in renal transplant recipients: a retrospective cohort study

P&T (Lawrenceville, N.J.), 2013-08, Vol.38 (8), p.484-488

2013

Volltextzugriff (PDF)

Genomics of BK viremia in kidney transplant recipients

Transplantation, 2014-02, Vol.97 (4), p.451-456

2014

Volltextzugriff (PDF)

Clinically Significant Drug−Drug Interaction Between Tacrolimus and Phenobarbital: The Price We Pay

Journal of pharmacy practice, 2010-12, Vol.23 (6), p.585-589

2010

Volltextzugriff (PDF)

Pretransplant anti-HLA-Cw and anti-HLA-DP antibodies in sensitized patients

Human immunology, 2012-09, Vol.73 (9), p.879-883

2012

Volltextzugriff (PDF)

1 – 25 von 46

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(45)
Mit Volltextzugriff
(36)

Publikationsform

Artikel
(46)

Sprache

Englisch
(46)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Desensitization Protocols and Their Outcome

Barriers and facilitators to community acceptability of integrating point-of-care testing to screen for sickle cell disease in children in primary healthcare settings in rural Upper East Region of Northern Ghana

Long-term Safety of Secukinumab Over Five Years in Patients with Moderate-to-severe Plaque Psoriasis, Psoriatic Arthritis and Ankylosing Spondylitis: Update on Integrated Pooled Clinical Trial and Post-marketing Surveillance Data

Bridging the Access Gap for Comprehensive Sickle Cell Disease Management Across Sub-Saharan Africa: Learnings for Other Global Health Interventions?

Evaluation of treatment patterns, healthcare resource utilization and cost of illness for sickle cell disease in Ghana: a private medical insurance claims database study

Clinical efficacy and safety of secukinumab in patients with psoriasis and comorbidities: pooled analysis of 4 phase 3 clinical trials

PB2512: SAFETY OF CRIZANLIZUMAB IN PATIENTS WITH SICKLE CELL DISEASE: INTEGRATED POST‐MARKETING SURVEILLANCE ANALYSIS

Clinical and economic analysis of short-course versus standard-course antithymocyte globulin (rabbit) induction therapy in deceased-donor renal transplant recipients

Tacrolimus Pharmacokinetic and Pharmacogenomic Differences between Adults and Pediatric Solid Organ Transplant Recipients

Reply to "Defining the benefits of desensitization therapy"

Barriers and Facilitators to Community Acceptability of Integrating Point-of-Care Testing to Screen for Sickle Cell Disease in Children in Primary Healthcare Settings in Rural Northern Ghana

Association of Secukinumab Treatment With Tuberculosis Reactivation in Patients With Psoriasis, Psoriatic Arthritis, or Ankylosing Spondylitis

Safety Profile of Crizanlizumab 5.0 Mg/Kg in Sickle Cell Disease: Pooled Data from Clinical Trials

15353 Presence of psoriatic arthritis has no impact on the clinical efficacy and safety of secukinumab in patients with psoriasis: Pooled analysis of four phase 3 clinical trials

Pretransplant immunologic risk assessment of kidney transplant recipients with donor-specific anti-human leukocyte antigen antibodies

Hyponatremia in Cirrhosis and End-Stage Liver Disease: Treatment with the Vasopressin V2-Receptor Antagonist Tolvaptan

P191 Secukinumab demonstrates a consistent safety profile in patients with psoriasis, psoriatic arthritis and ankylosing spondylitis over long term: updated pooled safety analyses

Lack of effect in desensitization with intravenous immunoglobulin and rituximab in highly sensitized patients

Hyponatremia in Cirrhosis and End-Stage Liver Disease: Treatment with the Vasopressin V^sub 2^-Receptor Antagonist Tolvaptan

Hyponatremia in Cirrhosis and End-Stage Liver Disease: Treatment with the Vasopressin V sub(2)-Receptor Antagonist Tolvaptan

Hyponatremia in Cirrhosis and End-Stage Liver Disease: Treatment with the Vasopressin V.sub.2-Receptor Antagonist Tolvaptan

Clinical outcomes after conversion from brand-name tacrolimus (prograf) to a generic formulation in renal transplant recipients: a retrospective cohort study

Genomics of BK viremia in kidney transplant recipients

Clinically Significant Drug−Drug Interaction Between Tacrolimus and Phenobarbital: The Price We Pay

Pretransplant anti-HLA-Cw and anti-HLA-DP antibodies in sensitized patients

Suchergebnisse filtern